# AVBP catalysts: ArriVent BioPharma, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/avbp/catalysts

> ArriVent BioPharma, Inc. (AVBP) has 2 upcoming catalysts. The next is the firmonertinib primary completion, February 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ArriVent BioPharma, Inc. |
| Ticker | AVBP (Nasdaq) |
| SEC CIK | 1868279 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/avbp |

## Cash runway

Cash $393.2M as of 2026-09-30; quarterly burn $40.7M; about 29.0 months of runway at that rate (XBRL company facts, accession 0001104659-26-124513).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2024 | [Firmonertinib trial start](https://sec-api.dev/pdufa/firmonertinib) | AVBP |  | completed | "In March 2024, ArriVent's clinical collaboration partner Beijing InnoCare Pharma Tech Co., Ltd., dosed the first patient in the Phase 1b combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000155837025002002/avbp-20250303xex99d1.htm)) |
| Q4 2024 | [Firmonertinib trial start](https://sec-api.dev/pdufa/firmonertinib) | AVBP | classical EGFR mutations | scheduled | "Initiation of dose expansion cohort for the ongoing Phase 1b trial evaluating firmonertinib in combination with SHP2 inhibitor ICP-189 by InnoCare in patients with classical EGFR mutations expected in the fourth quarter of 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000155837024015622/avbp-20241114xex99d1.htm)) |
| November 14, 2024 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000155837024015622/avbp-20241114xex99d1.htm)) |
| 2025 | [Firmonertinib topline data readout](https://sec-api.dev/pdufa/firmonertinib) | AVBP |  | scheduled | "We expect topline data in 2025 in our event-driven global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000155837025007259/avbp-20250512xex99d1.htm)) |
| March 3, 2025 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000155837025002002/avbp-20250303xex99d1.htm)) |
| May 12, 2025 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000155837025007259/avbp-20250512xex99d1.htm)) |
| August 11, 2025 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000155837025010974/avbp-20250811xex99d1.htm)) |
| November 10, 2025 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465925108839/avbp-20251110xex99d1.htm)) |
| Dec 2025 | [Firmonertinib trial start](https://sec-api.dev/pdufa/firmonertinib) | AVBP |  | completed | "In December 2025, we announced the first patient dosed and plan to enroll 480 patients in ALPACCA, a global, pivotal Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with PACC mutations being conducted jointly with Allist." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/avbp-20251231x10k.htm)) |
| early 2026 | [Firmonertinib topline data readout](https://sec-api.dev/pdufa/firmonertinib) | AVBP |  | scheduled | "Topline data expected in early 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000155837025011954/avbp-20250909xex99d1.htm)) |
| March 5, 2026 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465926024112/avbp-20260305xex99d1.htm)) |
| May 11, 2026 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/avbp-20260511xex99d1.htm)) |
| Q3 2026 | [ARR-002 trial start](https://sec-api.dev/pdufa/arr-002) | AVBP |  | scheduled | "Dosing of first patient with ARR-002 in a Phase 1 trial expected in the third quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/tm2622880d1_ex99-1.htm)) |
| 2H 2026 | [Firmonertinib topline data readout](https://sec-api.dev/pdufa/firmonertinib) | AVBP |  | scheduled | "Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/tm2622880d1_ex99-1.htm)) |
| August 11, 2026 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/tm2622880d1_ex99-1.htm)) |
| October 6, 2026 | [Furmonertinib primary completion](https://sec-api.dev/pdufa/furmonertinib) | AVBP |  | completed | "NCT05607550 (Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-06 (ACTUAL); Lead Sponsor ArriVent BioPharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05607550)) |
| Oct 2026 to Jan 2027 | [Furmonertinib topline data readout](https://sec-api.dev/pdufa/furmonertinib) | AVBP |  | scheduled | "NCT05607550 (Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-06 (ACTUAL); Lead Sponsor ArriVent BioPharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05607550)) |
| October 12, 2026 | [ARR-002 trial start](https://sec-api.dev/pdufa/arr-002) | AVBP |  | completed | "ArriVent Announces First Patient Dosed with" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465926115161/tm2627450d1_ex99-1.htm)) |
| November 6, 2026 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465926124484/tm2629343d1_ex99-1.htm)) |
| February 2029 | [Firmonertinib primary completion](https://sec-api.dev/pdufa/firmonertinib) | AVBP |  | scheduled | "NCT07185997 (Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor ArriVent BioPharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07185997)) |
| Feb to May 2029 | [Firmonertinib topline data readout](https://sec-api.dev/pdufa/firmonertinib) | AVBP |  | scheduled | "NCT07185997 (Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor ArriVent BioPharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07185997)) |

## Drugs

- [ARR-002](https://sec-api.dev/pdufa/arr-002): 
- [Firmonertinib](https://sec-api.dev/pdufa/firmonertinib): classical egfr mutations, Non-Small-Cell Lung Cancer
- [Furmonertinib](https://sec-api.dev/pdufa/furmonertinib): Metastatic Non-Small Cell Lung Cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/avbp/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AVBP catalysts: ArriVent BioPharma, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/avbp/catalysts

```bibtex
@misc{secapidev_companies_avbp_catalysts_20261116,
  title        = {AVBP catalysts: ArriVent BioPharma, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/avbp/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_avbp_catalysts_20261116","title":"AVBP catalysts: ArriVent BioPharma, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/avbp/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
